China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with US biotech firm BioMap last week. The collaboration aims to develop macromolecular drugs targeting tumors and autoimmune diseases using AI technology. BioMap, an AI-based drug discovery platform, was founded by Chinese internet giant Baidu’s CEO Robin Li and Baidu Ventures CEO Wei Liu.
Collaboration Details
The partnership will focus on the full development process of macromolecular drugs, including the construction of AI-exclusive large models and AI intelligent laboratories. This comprehensive approach leverages BioMap’s advanced AI capabilities and Kexing Biopharm’s expertise in drug development to accelerate the creation of novel therapies for cancer and autoimmune conditions.
Strategic Significance
The collaboration highlights the growing trend of integrating AI into drug discovery and development. By combining Kexing Biopharm’s biological expertise with BioMap’s AI-driven platform, the companies aim to improve the efficiency and success rate of developing complex macromolecular drugs. Financial specifics of the partnership were not disclosed.-Fineline Info & Tech
Leave a Reply